Samrat Pharmachem Ltd Faces Sharp Valuation Reassessment Amid Market Pressure

Valuation Metrics Signal Elevated Risk

Recent data reveals that Samrat Pharmachem’s P/E ratio has plunged to -38.81, a stark contrast to its previous standing and a clear indication of negative earnings or significant losses. This negative P/E ratio places the company in the ‘risky’ valuation category, diverging markedly from its pharmaceutical peers. For context, Bliss GVS Pharma trades at a fair P/E of 21.22, while Shukra Pharma and NGL Fine Chem are classified as very expensive with P/E ratios of 63.22 and 40.02 respectively.

The price-to-book value ratio has also shifted, now standing at 0.92, suggesting the stock is trading below its book value. While a P/BV below 1 can sometimes indicate undervaluation, in this case it reflects underlying financial stress, especially when combined with other negative indicators. The enterprise value to EBITDA (EV/EBITDA) ratio has deteriorated even more dramatically to -56.78, underscoring operational challenges and weak earnings before interest, taxes, depreciation, and amortisation.

Other valuation multiples such as EV to EBIT (-38.63) and EV to capital employed (0.91) further reinforce the precarious financial position. The PEG ratio remains at zero, indicating no growth premium is currently priced in, while the dividend yield is a modest 0.47%, reflecting limited shareholder returns.

Operational Performance and Returns

Samrat Pharmachem’s return on capital employed (ROCE) is a low 5.41%, signalling inefficient use of capital relative to its peers. More concerning is the negative return on equity (ROE) of -2.38%, highlighting losses at the shareholder level. These figures contrast sharply with industry standards where companies typically maintain positive ROCE and ROE to justify valuations.

The stock’s recent price action has been notably weak. On 17 Feb 2026, the share price closed at ₹211.00, down 11.57% from the previous close of ₹238.60. The 52-week high was ₹425.00, while the low was ₹195.10, indicating a significant retracement from peak levels. Intraday volatility was also evident, with the price ranging between ₹210.00 and ₹230.00.

Comparative Returns Highlight Underperformance

When benchmarked against the Sensex, Samrat Pharmachem’s returns have been disappointing. Over the past week, the stock declined by 11.29% compared to a modest 0.94% drop in the Sensex. The one-month and year-to-date returns were -6.41% and -7.17% respectively, both underperforming the Sensex’s -0.35% and -2.28% returns.

Longer-term performance is even more concerning. Over one year, the stock lost 37.68% while the Sensex gained 9.66%. Over three years, Samrat Pharmachem’s cumulative return was a negative 58.69%, in stark contrast to the Sensex’s 35.81% gain. Even over five years, the stock’s 46.58% return lags behind the Sensex’s 59.83%. However, the ten-year return of 583.95% remains impressive, outperforming the Sensex’s 259.08%, reflecting strong historical growth that has since reversed.

Peer Comparison Highlights Valuation Disparity

Within the Pharmaceuticals & Biotechnology sector, Samrat Pharmachem’s valuation stands out as particularly unfavourable. While companies like Bliss GVS Pharma and Syncom Formulations maintain fair valuations with P/E ratios around 18-21 and EV/EBITDA multiples in the 10-16 range, Samrat’s negative multiples signal distress. Other peers such as Shukra Pharma, NGL Fine Chem, and Hester Bios are classified as very expensive, trading at P/E multiples exceeding 30, yet they maintain positive earnings and growth prospects.

Interestingly, some companies like TTK Healthcare are deemed attractive with a P/E of 18.77 and a high PEG ratio of 7.98, reflecting strong growth expectations. In contrast, Samrat Pharmachem’s PEG ratio of zero indicates no anticipated growth, further undermining its valuation appeal.

Market Capitalisation and Mojo Score

Samrat Pharmachem holds a market cap grade of 4, indicating a mid-sized market capitalisation within its sector. However, its overall Mojo Score has deteriorated to 3.0, with the Mojo Grade downgraded from Sell to Strong Sell as of 19 Aug 2025. This downgrade reflects the combined impact of deteriorating fundamentals, weak price performance, and unfavourable valuation metrics.

Investors should note that the company’s financial health and market sentiment have shifted considerably, warranting caution. The downgrade to Strong Sell by MarketsMOJO underscores the heightened risk profile and diminished attractiveness of the stock at current levels.

Investment Implications and Outlook

The sharp decline in valuation multiples and the downgrade to Strong Sell suggest that Samrat Pharmachem Ltd is currently facing significant headwinds. The negative earnings and poor returns on capital highlight operational challenges that have eroded investor confidence. While the stock’s price has retraced substantially from its 52-week high of ₹425.00 to ₹211.00, the underlying fundamentals do not yet support a recovery.

Investors should weigh the risks carefully, considering the company’s weak financial metrics and unfavourable peer comparison. The low dividend yield and negative ROE further diminish the stock’s appeal as a value or income investment. Unless there is a marked improvement in earnings and capital efficiency, the valuation is likely to remain under pressure.

Long-term investors who have benefited from the company’s impressive ten-year return of 583.95% may need to reassess their positions in light of recent performance and valuation deterioration. The broader pharmaceutical sector continues to offer opportunities, but Samrat Pharmachem’s current risk profile suggests caution.

Conclusion

Samrat Pharmachem Ltd’s valuation parameters have shifted from previously expensive levels to a risky zone, driven by negative earnings, poor returns, and a steep price decline. The downgrade to Strong Sell by MarketsMOJO reflects these challenges and signals a need for investors to reconsider exposure. Comparative analysis with peers highlights the company’s relative underperformance and valuation disconnect. Until operational and financial metrics improve, the stock’s attractiveness remains limited.

Unlock special upgrade rates for a limited period. Start Saving Now →